Search

Displaying results 3281 - 3290 of 10000 in total
  1. Drug

    Cythioate

    go.drugbank.com/drugs/DB11392
    ExperimentalVet approved

    Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of

  3. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  4. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.

  5. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency.

  6. Drug

    Cobalt chloride

    go.drugbank.com/drugs/DB14206
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.

  8. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

  9. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.

  10. Drug

    Tenoxicam

    go.drugbank.com/drugs/DB00469
    ApprovedInvestigational

    Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.